Ertapenem

C. diff Risk

Medium

Oral Bioavailability

NA

Approximate Cost

Dosing

Adult

1g IV q24h

Renal

CrCl Greater Than 30 mL/min
1 g q24h

CrCl Less Than 30 mL/min
500 mg q24h

General Information

Common Usage

Targeted therapy of ESBL infections and other resistant gram negative infections.

Empiric therapy when broad spectrum of carbapenems is desired without the need for anti-pseudomonal activity.

Adverse Effects

  • Immediate and delayed-type allergy

  • GI disturbance

  • Cytopenias, eosinophilia, positive Coombs

  • Liver enzyme abnormalities

  • Seizure risk lower than other carbapenems

Pharmacology

Antimicrobial class: Carbapenem

Pregnancy category: B

Average serum half life: 4 hours

Urine penetration: Therapeutic

Lung penetration: Therapeutic

Biliary penetration: Moderate